Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma
June 16th 2021Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.
Lenalidomide Added to Rituximab Following Resistance Leads to Progression Delay in Lymphomas
June 16th 2021Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.
Teclistamab at Recommended Phase 2 Dose Shows Promising Results in R/R Myeloma
June 8th 2021According to updated results presented during the 2021 ASCO Annual Meeting, teclistamab administered at the recommended phase 2 dose demonstrated encouraging safety and efficacy among patients with relapsed/refractory multiple myeloma treated in a first-in-human phase 1 trial.
Fracture Risk Reduced by BPAs During Radium-223/Enzalutamide Combo Treatment In mCRPC
June 8th 2021The risk of fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer was controlled by the use of bone-protecting agents during treatment with radium-223 plus enzalutamide.
In Some Heavily Pretreated Patients with R/R MM Ide-Cel Continues to Show Deep and Durable Responses
June 4th 2021Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor T-cell therapy, idecabtagene vicleucel, continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.
Adjuvant Chemotherapy Does Not Improve 5-Year Overall Survival in Locally Advanced Cervical Cancer
June 3rd 2021In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.
Nivolumab/Chemotherapy Improves PCR as Neoadjuvant Treatment of Resectable NSCLC
April 10th 2021Neoadjuvant nivolumab added to chemotherapy lead to an improvement in pathological complete responses, compared with chemotherapy alone, as treatment of patients with resectable non-small cell lung cancer.
Staging of Nonmetastatic Relapsed Prostate Cancer May Be Aided by PSMA-Directed PET Tracer
February 12th 2021A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.
Stem Cells Achieve Potent Immunity Against SARS-CoV2 and Common Human Coronaviruses In Patients
February 8th 2021Finding presented on patients with hematologic malignancies at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR show that patients who had undergone a hematopoietic stem cell transplantation can accumulate effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses.
Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL
January 16th 2021The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Subcutaneous Daratumumab Triplet Improves PFS in R/R Multiple Myeloma
December 7th 2020In the phase 3 APOLLO study, patients with relapsed/refractory multiple myeloma who had received 1 or more prior line of therapy had a significantly reduced the risk of progression or death by 37% when treated with the combination of subcutaneous daratumumab to pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone.
OS With Olaparib Bests Androgen Receptor Inhibitors in Certain Men With mCRPC
September 20th 2020Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.
OS Benefit Observed With Frontline Nivolumab/Ipilimumab Plus Limited Chemotherapy in NSCLC
May 29th 2020"CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival curves and lower progressive disease rates as best overall response, the hypothesis for this study design was validated."
Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
May 29th 2020"Based on these results, we note that the combination of nivolumab and ipilimumab, which is now approved by the United States FDA, is a novel chemotherapy-sparing first-line treatment approach for advanced-stage non-small-cell lung cancer."
Responses Observed With T-DXd May Change Standard of Care in Advanced HER2+ Breast Cancer
December 11th 2019In heavily pretreated patients with advanced HER2-positive breast cancer, trastuzumab deruxtecan induced a confirmed objective response rate of almost 61% and a durable benefit, according to results from the phase II DESTINY-Breast01 trial presented at the 2019 San Antonio Breast Cancer Symposium.
Venetoclax/Obinutuzumab Combo Advances PFS in Previously Untreated CLL
June 5th 2019According to the pivotal phase III CLL14 study presented during the 2019 American Society of Clinical Oncology Annual Meeting, venetoclax plus obinutuzumab demonstrated a lengthening in progression-free survival time for patients with previously untreated chronic lymphocytic leukemia compared with obinutuzumab plus chlorambucil. Trial results show that the chemotherapy-free combination reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil.